View Past PerformanceCharming Medical バランスシートの健全性財務の健全性 基準チェック /46Charming Medicalの総株主資本は$49.2K 、総負債は$314.2Kで、負債比率は638.1%となります。総資産と総負債はそれぞれ$5.4Mと$5.3Mです。 Charming Medicalの EBIT は$1.6Mで、利息カバレッジ比率-37です。現金および短期投資は$2.8Mです。主要情報638.11%負債資本比率US$314.23k負債インタレスト・カバレッジ・レシオ-37x現金US$2.76mエクイティUS$49.24k負債合計US$5.31m総資産US$5.36m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 28Charming Medical Limited Announces Resignation of Independent Director Josephine Yan Yeung, Effective March 27, 2026Charming Medical Limited announced that on March 27, 2026, Ms. Josephine Yan Yeung notified the Company of her resignation as an independent director, effective March 27, 2026, in order to pursue other business commitments. On March 27, 2026, the Board of Directors of the Company accepted and approved Ms. Yeung's resignation. The Company is in the process of identifying a suitable replacement and expects to fill the vacancy by April 2, 2026.お知らせ • Jan 08Charming Medical Limited Announces Board ChangesCharming Medical Limited on December 23, 2025, Mr. Leut Ming Gung notified the Company of his resignation as an independent director, effective December 31, 2025, in order to pursue other business commitments. Mr. Gung’s resignation was not a result of any disagreement with the Company’s operations, policies, or procedures. On January 5, 2026, the Board of Directors of the Company accepted and approved Mr. Gung’s resignation. On January 5, 2026, the Board of Directors, Nominating Committee, and the Compensation Committee approved by resolutions and confirmed the appointment of Mr. Yin Jiang as a director of the Company, with an annual compensation of HKD 240,000, effective upon approval of the resolutions, until his successor is duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined Mr. Jiang is an “independent” director under applicable U.S. Securities and Exchange Commission and Nasdaq Marketplace Rules. Mr. Jiang will be serving on the Board of Directors as a non-employee, independent director. Mr. Jiang has also been named as the chairman of the Compensation Committee and a member of the Audit Committee and Nominating Committee of the Company. Mr. Jiang has been involved in fund management activities since 2016. In 2017, he founded Panshi Capital, a private equity fund, which was acquired in 2019 by a multi-billion RMB institution in China. He also has experience in artificial intelligence and blockchain technologies and holds multiple invention patents and software copyrights in these fields. In 2013, Mr. Jiang founded Panzhong Technology Co. Ltd., a technology company focused on fiber-optic communication and high-performance computing applications. From 2004 to 2013, he served as a software test engineer at Cisco WebEx. Mr. Jiang received a Bachelor of Science degree in Applied Physics from the University of Science and Technology of China in 2004 and holds a securities investment fund qualification certificate issued by the Asset Management Association of China.お知らせ • Dec 20Robbins LLP Informs Investors of the Charming Medical, Limited Securities Class ActionRobbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited securities between October 10, 2025 and November 12, 2025. The Company claims to "enhance the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology." The Allegations: Robbins LLP is Investigating Allegations that Charming Medical, Limited (MCTA) Engaged in a Fraudulent Stock Promotion Scheme. According to the complaint, defendants failed to disclose that: (1) Charming was the subject of a fraudulent stock promotion scheme involving social media based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; and (3) Charming's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price. Plaintiff alleges that in the weeks leading up to November 12, 2025, Charming's share price surged from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news from the Company justifying such a spike. Investigations and public reports have revealed that Charming's stock became the subject of an illicit social-media-based promotion scheme that artificially inflated its price. These reports detail how impersonators claiming to be legitimate financial advisors touted Charming in online forums, chat groups, and through social media posts with sensational, but baseless, claims to create a buying frenzy among retail investors. On November 12, 2025, the SEC halted trading of Charming's stock. The stock remains halted because the Company has not provided the information regulators required to lift the suspension.Board Change • Oct 22High number of new directorsIndependent Director Josephine Yeung was the last director to join the board, commencing their role in 2025.お知らせ • Oct 21Charming Medical Limited has completed an IPO in the amount of $6.4 million.Charming Medical Limited has completed an IPO in the amount of $6.4 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: $4 Discount Per Security: $0.28財務状況分析短期負債: MCTAの 短期資産 ( $3.4M ) は 短期負債 ( $4.9M ) をカバーしていません。長期負債: MCTAの短期資産 ( $3.4M ) が 長期負債 ( $358.0K ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: MCTA総負債よりも多くの現金を保有しています。負債の削減: MCTAの負債対資本比率が過去 5 年間で減少したかどうかを判断するにはデータが不十分です。債務返済能力: MCTAの負債は 営業キャッシュフロー によって 十分にカバー されています ( 135.5% )。インタレストカバレッジ: MCTA支払う利息よりも稼ぐ利息の方が多いので、利息支払い の補償は問題になりません。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YConsumer-services 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/08 23:15終値2025/11/11 00:00収益2025/03/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Charming Medical Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 28Charming Medical Limited Announces Resignation of Independent Director Josephine Yan Yeung, Effective March 27, 2026Charming Medical Limited announced that on March 27, 2026, Ms. Josephine Yan Yeung notified the Company of her resignation as an independent director, effective March 27, 2026, in order to pursue other business commitments. On March 27, 2026, the Board of Directors of the Company accepted and approved Ms. Yeung's resignation. The Company is in the process of identifying a suitable replacement and expects to fill the vacancy by April 2, 2026.
お知らせ • Jan 08Charming Medical Limited Announces Board ChangesCharming Medical Limited on December 23, 2025, Mr. Leut Ming Gung notified the Company of his resignation as an independent director, effective December 31, 2025, in order to pursue other business commitments. Mr. Gung’s resignation was not a result of any disagreement with the Company’s operations, policies, or procedures. On January 5, 2026, the Board of Directors of the Company accepted and approved Mr. Gung’s resignation. On January 5, 2026, the Board of Directors, Nominating Committee, and the Compensation Committee approved by resolutions and confirmed the appointment of Mr. Yin Jiang as a director of the Company, with an annual compensation of HKD 240,000, effective upon approval of the resolutions, until his successor is duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined Mr. Jiang is an “independent” director under applicable U.S. Securities and Exchange Commission and Nasdaq Marketplace Rules. Mr. Jiang will be serving on the Board of Directors as a non-employee, independent director. Mr. Jiang has also been named as the chairman of the Compensation Committee and a member of the Audit Committee and Nominating Committee of the Company. Mr. Jiang has been involved in fund management activities since 2016. In 2017, he founded Panshi Capital, a private equity fund, which was acquired in 2019 by a multi-billion RMB institution in China. He also has experience in artificial intelligence and blockchain technologies and holds multiple invention patents and software copyrights in these fields. In 2013, Mr. Jiang founded Panzhong Technology Co. Ltd., a technology company focused on fiber-optic communication and high-performance computing applications. From 2004 to 2013, he served as a software test engineer at Cisco WebEx. Mr. Jiang received a Bachelor of Science degree in Applied Physics from the University of Science and Technology of China in 2004 and holds a securities investment fund qualification certificate issued by the Asset Management Association of China.
お知らせ • Dec 20Robbins LLP Informs Investors of the Charming Medical, Limited Securities Class ActionRobbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited securities between October 10, 2025 and November 12, 2025. The Company claims to "enhance the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology." The Allegations: Robbins LLP is Investigating Allegations that Charming Medical, Limited (MCTA) Engaged in a Fraudulent Stock Promotion Scheme. According to the complaint, defendants failed to disclose that: (1) Charming was the subject of a fraudulent stock promotion scheme involving social media based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; and (3) Charming's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price. Plaintiff alleges that in the weeks leading up to November 12, 2025, Charming's share price surged from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news from the Company justifying such a spike. Investigations and public reports have revealed that Charming's stock became the subject of an illicit social-media-based promotion scheme that artificially inflated its price. These reports detail how impersonators claiming to be legitimate financial advisors touted Charming in online forums, chat groups, and through social media posts with sensational, but baseless, claims to create a buying frenzy among retail investors. On November 12, 2025, the SEC halted trading of Charming's stock. The stock remains halted because the Company has not provided the information regulators required to lift the suspension.
Board Change • Oct 22High number of new directorsIndependent Director Josephine Yeung was the last director to join the board, commencing their role in 2025.
お知らせ • Oct 21Charming Medical Limited has completed an IPO in the amount of $6.4 million.Charming Medical Limited has completed an IPO in the amount of $6.4 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: $4 Discount Per Security: $0.28